Pharmacoeconomical analysis of the use of upadacitinib, baricitinib and dupilumab for systemic therapy of patients with moderate and severe atopic dermatitis

Objective . Comparative pharmacoeconomic evaluation of upadacitinib, baricitinib and dupilumab for the treatment moderate to severe atopic dermatitis. Materials methods Study design — retrospective. Pharmacoeconomic analysis method cost-effectiveness analysis, budget impact analysis. Data sources. On effectiveness compared alternatives meta-analysis randomized clinical trials drugs, recommendations; on cost drugs state register maximum selling prices. Results Lowest (CER) values both EASI-75 EASI-90 responses were upadacitinib. For upadacitinib 15 mg/day, achieving was reduced by 63.9 70.3%, respectively 44.2 46.8% baricitinib. 30 reduction in effect will be, respectively, 40.8 56.2%, with 8,5 21.4%. The (BIA) showed that increase share from 35%, proportion 5 10% due a decrease patients, receiving reduce patients dermatitis scale Russian Federation total 11.6% (RUB 1.25 billion) single-step change first year 7.9% 0.86 gradual over 3 years. An missed opportunities if changes 35% 741 can be additionally provided therapy year, 629 second 567 third (with target population size 4929 patients). Conclusion Increasing not only significantly burden healthcare system refusing use more expensive some but also goals terms EASI-90.